High levels of confusion for cholesterol awareness campaigns

Medical Journal of Australia

Volumn 189, Issue 6, 2008, Pages 326-328

  Hall, Danika V ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CHOLESTEROL; TERBINAFINE;

ADVERTIZING; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG MARKETING; GENERAL PRACTITIONER; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; MEDICAL PRACTICE; MEDICAL SOCIETY; PRESCRIPTION; PUBLIC HEALTH; SCREENING TEST;

EID: 53549117121     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2008.tb02051.x     Document Type: Article

References (17)

1. Cresswell A. 10pc less cholesterol "will save 3000 lives". The Australian 2008; 13 Mar. http://www.theaustralian.news.com.au/story/ 0,25197,23366060-23289,00.html (accessed Jul 2008).
2. Unilever Australasia. National Cholesterol Education Program of Australia [website]. http://www.ncepa.com.au (accessed Mar 2008).
3. Unilever Australasia. Flora pro-activ Test the Nation [campaign brochure]. Sydney: Unilever Australasia, 2008.
4. Unilever Australasia. Flora pro-activ Test the Nation [website]. http://www.testthenation.com.au (accessed Mar 2008).
5. Australian Government Department of Health and Ageing. Therapeutic Goods Advertising Code 2007. Canberra: Australian Government, 2007.
6. Pfizer Australia. Cholesteroltest [website]. http://www.cholesteroltest.com.au (accessed Mar 2008).
7. Pfizer Australia. A new campaign to put the spotlight on high cholesterol [advertisement]. Australian Doctor 2008; 7 Mar: 9.
8. Tonkin A, Barter P, Best J, et al; National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand. Position statement on lipid management - 2005. Heart Lung Circ 2005; 14:275-291.
9. Heart Foundation. Lipid management guidelines 2001 - summary paper. Canberra: National Heart Foundation, 2001. http://www.heartfoundation.org.au/document/NHF/ guideline_lipid_summary_2001.pdf Mar accessed)
10. Australian Government Department of Health and Ageing. PBS for health professionals. General statement for lipid-lowering drugs prescribed as pharmaceutical benefits. http://www.pbs.gov.au/html/healthpro/browseby/ explanatory-notes?ref=section2-gec10 (accessed Apr 2008).
11. Parry V. The art of branding a condition. Med Mark Media 2003; 38 (5):43-49.
12. Angelmar R, Angelmar S, Kane L.,Building strong condition brands. J Med Mark 2007; 7: 341-351.
13. Pfizer. Lipitor [websitel. http://www.lipitor.com (accessed Mar 2008).
14. Australian Institute of Health and Welfare. Statistics on drug use in Australia 2002. Canberra: AIHW, 2003. (AIHW Cat. No. PHE 43.)
15. Mintzes B. Disease mongering in drug promotion: do governments have a regulatory role? PLoS Med 2006; 3 (4): e198. doi: 10.1371/ journal.pmed.0030198.
16. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ 2002; 324: 886-891.
17. 't Jong GW, Stricker BHC, Sturkenboom MCJM. Marketing in the lay media and prescriptions of terbinafine in primary care: Dutch cohort study. BMJ 2004; 328: 931. doi: 10.1136/bmj.38007.711481.F7.